Literature DB >> 19896696

H3K4 dimethylation in hepatocellular carcinoma is rare compared with other hepatobiliary and gastrointestinal carcinomas and correlates with expression of the methylase Ash2 and the demethylase LSD1.

Christian Magerl1, Jörg Ellinger, Till Braunschweig, Elisabeth Kremmer, Lin Kristin Koch, Tobias Höller, Reinhard Büttner, Bernhard Lüscher, Ines Gütgemann.   

Abstract

Methylation of core histones regulates chromatin structure and gene expression. Recent studies have demonstrated that these methylation patterns have prognostic value for some tumors. Therefore, we investigated dimethylation of histone H3 at lysine 4 (H3K4diMe) and H3K4 methylating (Ash2 complex) and demethylating enzymes (LSD1) in carcinomas of the hepatic and gastrointestinal tract. High levels of H3K4diMe were rarely observed in 15.7% of hepatocellular carcinoma (8/51) unlike other carcinomas including, in ascending order, cholangiocellular carcinoma/adenocarcinoma of the extrahepatic biliary tract, gastric carcinoma, pancreatic ductal adenocarcinoma, and neuroendocrine carcinoma (P < .001). Ash2 was expressed in 84.4% of hepatocellular carcinomas (38/45) and correlated directly with H3K4diMe modification (correlation coefficient r = 0.53) and LSD1 expression (r = 0.35). In contrast to other carcinomas, 65.9% (29/44) of hepatocellular carcinomas analyzed showed no LSD1 expression (P < .001). Interestingly, hepatocellular carcinomas without LSD1 expression appeared to be frequently Ash2 and H3K4diMe weak or negative (P = .004). In summary, high H3K4diMe expression is rare in hepatocellular carcinoma compared with other carcinomas (negative predictive value 92.3%), which may aid in the differential diagnosis. Lack of H3K4diMe is possibly due to complex epigenetic regulation involving Ash2 and LSD1. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19896696     DOI: 10.1016/j.humpath.2009.08.007

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  32 in total

1.  Histone Methylation by Temozolomide; A Classic DNA Methylating Anticancer Drug.

Authors:  Tieli Wang; Amanda J Pickard; James M Gallo
Journal:  Anticancer Res       Date:  2016-07       Impact factor: 2.480

Review 2.  Epigenetic changes in gastroenteropancreatic neuroendocrine tumours.

Authors:  P Mapelli; E O Aboagye; J Stebbing; R Sharma
Journal:  Oncogene       Date:  2014-12-01       Impact factor: 9.867

3.  Helicobacter pylori regulates iNOS promoter by histone modifications in human gastric epithelial cells.

Authors:  Tiziana Angrisano; Francesca Lembo; Silvia Peluso; Simona Keller; Lorenzo Chiariotti; Raffaela Pero
Journal:  Med Microbiol Immunol       Date:  2012-01-05       Impact factor: 3.402

Review 4.  Chromatin dynamics: H3K4 methylation and H3 variant replacement during development and in cancer.

Authors:  Moonmoon Deb; Swayamsiddha Kar; Dipta Sengupta; Arunima Shilpi; Sabnam Parbin; Sandip K Rath; Vedang A Londhe; Samir Kumar Patra
Journal:  Cell Mol Life Sci       Date:  2014-03-28       Impact factor: 9.261

5.  The deubiquitinase USP28 stabilizes LSD1 and confers stem-cell-like traits to breast cancer cells.

Authors:  Yadi Wu; Yifan Wang; Xiuwei H Yang; Tiebang Kang; Yongxiang Zhao; Chi Wang; B Mark Evers; Binhua P Zhou
Journal:  Cell Rep       Date:  2013-09-26       Impact factor: 9.423

Review 6.  Pathogenic and Therapeutic Role of H3K4 Family of Methylases and Demethylases in Cancers.

Authors:  Aman Kumar; Niti Kumari; Nayudu Nallabelli; Rajendra Prasad
Journal:  Indian J Clin Biochem       Date:  2019-04-03

7.  Discovery of [1,2,3]Triazolo[4,5-d]pyrimidine Derivatives as Novel LSD1 Inhibitors.

Authors:  Zhong-Hua Li; Xue-Qi Liu; Peng-Fei Geng; Feng-Zhi Suo; Jin-Lian Ma; Bin Yu; Tao-Qian Zhao; Zhao-Qing Zhou; Chen-Xi Huang; Yi-Chao Zheng; Hong-Min Liu
Journal:  ACS Med Chem Lett       Date:  2017-03-06       Impact factor: 4.345

Review 8.  DNA and histone methylation in gastric carcinogenesis.

Authors:  Danielle Queiroz Calcagno; Carolina Oliveira Gigek; Elizabeth Suchi Chen; Rommel Rodriguez Burbano; Marília de Arruda Cardoso Smith
Journal:  World J Gastroenterol       Date:  2013-02-28       Impact factor: 5.742

9.  Triazole-dithiocarbamate based selective lysine specific demethylase 1 (LSD1) inactivators inhibit gastric cancer cell growth, invasion, and migration.

Authors:  Yi-Chao Zheng; Ying-Chao Duan; Jin-Lian Ma; Rui-Min Xu; Xiaolin Zi; Wen-Lei Lv; Meng-Meng Wang; Xian-Wei Ye; Shun Zhu; David Mobley; Yan-Yan Zhu; Jun-Wei Wang; Jin-Feng Li; Zhi-Ru Wang; Wen Zhao; Hong-Min Liu
Journal:  J Med Chem       Date:  2013-11-01       Impact factor: 7.446

10.  Mechanism for DPY30 and ASH2L intrinsically disordered regions to modulate the MLL/SET1 activity on chromatin.

Authors:  Young-Tae Lee; Alex Ayoub; Sang-Ho Park; Liang Sha; Jing Xu; Fengbiao Mao; Wei Zheng; Yang Zhang; Uhn-Soo Cho; Yali Dou
Journal:  Nat Commun       Date:  2021-05-19       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.